Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of VX-548 in Hepatic Impairment
NCT05560464Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of suzetrigine in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration of VX-548, Area Under the Plasma Concentration Versus Time Curve During a Dosing Interval of VX-548 and 5 more. Started Oct 2022; status: completed.
02
Drugs
suzetrigine
03
Conditions
pain
Beyond the preview
Go deeper on NCT05560464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560464.